Three Decades of Transaction Execution.
Transaction Execution
Over one billion dollars in aggregate transaction value across public offerings, M&A, and restructurings in life sciences and beyond.
My unique value
By The Numbers.
30+
Years in Life Sciences Finance
Track Record
Selected Portfolio
Recent engagements include supporting Vyome Holdings' Nasdaq listing and advising clinical-stage and revenue-stage companies across oncology, CNS, dermatology, and rare disease.
Current Clients
Advisory Portfolio
As Managing Director of Foresite Advisors, Robert has served as fractional CFO and transaction advisor to a broad portfolio of public and private biotechnology and medical device companies — from early clinical stage through commercial operations.
Engagements span capital formation, public listing readiness, reverse mergers, SPAC transactions, venture debt financing, and strategic alternatives — always working alongside management teams and boards to translate scientific ambition into executable financial strategy.
Therapeutic Focus
Sector Depth
Robert's sector experience spans oncology, neurodegenerative and ophthalmic disease, autoimmune and inflammatory conditions, regenerative medicine and stem cell therapeutics, and infectious disease — across companies ranging from early clinical-stage biotechs to revenue-generating public companies.